The controversy surrounding fetal lung maturity in diabetes in pregnancy: a re-evaluation.
It is beyond the scope of this article to discuss the biochemical markers of fetal lung maturity and their pathophysiological characteristics. This information can be found in several textbooks and review articles. Instead, this article addresses controversial issues that confront the obstetrician in daily clinical practice related to the role of diabetes (glucose) as the teratogen for lung morbidity, and the association between lung maturity testing results and actual lung morbidity.
Langer
O
O
Department of Obstetrics and Gynecology, St. Luke's-Roosevelt Hospital Center, University Hospital of Columbia University, New York, New York 10019, USA.
D001786:Blood Glucose / Q000378:metabolism; D016640:Diabetes, Gestational / Q000097:blood / Q000503:physiopathology*; D005260:Female; D005325:Fetal Organ Maturity / Q000502:physiology*; D005865:Gestational Age; D006801:Humans; D008168:Lung / Q000196:embryology*; D011247:Pregnancy; D011254:Pregnancy in Diabetics / Q000097:blood / Q000503:physiopathology*; D011295:Prenatal Care
D001786:Blood Glucose